News Release #9- Can Regenerative Organ Tissue Replacement Procedures Eliminate Liver Transplants?
Updated: May 23
Can New Regenerative Organ Tissue Replacement Procedures Eliminate Liver Transplants?
Chronic liver disease occurs throughout the world irrespective of age, sex, region or race. Cirrhosis is an end result of a variety of liver diseases characterized by fibrosis and architectural distortion of the liver with the formation of regenerative nodules and can have varied clinical manifestations and complications.
Since 2000, liver diseases have annually risen to become one of the leading causes of death and illness. The World Health Organization (WHO), reports that about 46% of global diseases and 59% of the world mortality is because of chronic liver diseases and approximately 35 million people in the world die of chronic diseases annually.
In the United States, there are over 17,000 patients on the transplant liver waiting list, but there are only enough donated livers to perform about 5,000 transplants per year. As a result, more than 1,700 patients die each year while on liver waiting lists. In addition, each year in the United States, about 21,000 men and 8,000 women get liver cancer, and about 16,000 men and 6,000 women die from the disease.
More than 5 million people are living with chronic Hepatitis B or chronic Hepatitis C in the United States. Approximately 20% to 25% cases of liver cirrhosis are from the Hepatitis C virus (HCV) infection. An estimated 1.4 million people in the United States are living with chronic hepatitis B infection.
These facts clearly indicate the need for a new approach to liver disease. One effective liver solution regenerates the patient’s existing liver, in-place (“the in the body solution”), and in creating this fix, uses the patient’s DNA to assure an exact tissue replacement match.
This excellent liver disease solution is scheduled to be available for general delivery to liver patients in from 18 to 24 months. The solution Company, BCM Industries, is currently continuing product trials. In parallel, BCM is designing and constructing a volume production manufacturing facilities to initially service the liver replacement needs of thousands of liver patients. To learn how and follow the progress, review the information provided at the BCM Industries and the RTH Foundation websites.
Sources: Columbia University Irving Medical Center. dn1.polaris.com/globalassets/taylor-dunn/2019/model/brochures/c-426ac-brochure.pdf?v=6431d239&_ga=2.77420309.1036521863.1550549042-1463092286.1550549042 The Regents of The University of California. https://www.ucsfhealth.org/education/living-donor-liver-transplant-the-facts BMJ Publishing Group Ltd- Mortality due to cirrhosis and liver cancer in the United States, 1999-2016; https://www.bmj.com/content/362/bmj.k2817 World Gastroenterology Organization. https://www.worldgastroenterology.org/publications/e-wgn/e-wgn-expert-point-of-view-articlescollection/global-burden-of-liver-disease-a-true-burden-on-health-sciences-and-economies American Liver Foundation https://liverfoundation.org/liver-disease-statistics/#alcohol-related-liver-disease-and-cirrhosis Frontline Medical Communications Inc. https://www.mdedge.com/jcomjournal/article/184170/hepatology/us-death-rates-chronic-liver-disease-continue-rise European Association for the Study of the Liver. https://www.journal-of-hepatology.eu/article/S0168-8278(19)30140-0/fulltext